Najmeh Alirezaie , Anne-Laure Chong , Felix K.F. Kommoss , Nelly Sabbaghian , Jose Camacho Valenzuela , Dylan Pelletier , Javad Nadaf , Shailesh B. Kolekar , Pradeesh Sivapalan , Mark G. Evans , Paul S. Thorner , Pierre-Olivier Fiset , Andreas von Deimling , William D. Foulkes
{"title":"肺泡瘤的外显子和表观基因组分析","authors":"Najmeh Alirezaie , Anne-Laure Chong , Felix K.F. Kommoss , Nelly Sabbaghian , Jose Camacho Valenzuela , Dylan Pelletier , Javad Nadaf , Shailesh B. Kolekar , Pradeesh Sivapalan , Mark G. Evans , Paul S. Thorner , Pierre-Olivier Fiset , Andreas von Deimling , William D. Foulkes","doi":"10.1016/j.lungcan.2024.107916","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Pulmonary blastoma is a rare, biphasic, adult-onset lung tumor. In this study, we investigate whether DICER1 pathogenic variants are a feature of pulmonary blastomas through in-depth analysis of the molecular events defining them.</p></div><div><h3>Methods</h3><p>We performed exome-wide sequencing and DNA methylation profiling of 8 pulmonary blastomas from 6 affected persons.</p></div><div><h3>Results</h3><p>We identified biallelic somatic <em>DICER1</em> pathogenic variants in 7 of 8 cases. The remaining case had a solitary missense pathogenic variant in the RNase IIIb domain of DICER1. Six of 8 cases carried a <em>CTNNB1</em> hotspot variant and 4 of 8 had a somatic pathogenic variant in <em>TP53</em>. Methylation analysis showed that the pulmonary blastomas clustered with other <em>DICER1</em>-mutated tumors and not with other more common types of lung cancer.</p></div><div><h3>Conclusion</h3><p>We conclude somatic <em>DICER1</em> pathogenic variants are the major driver of pulmonary blastoma and are likely to act in conjunction with <em>CTNNB1</em> hotspot variants that are often present.</p></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"195 ","pages":"Article 107916"},"PeriodicalIF":4.5000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exomic and epigenomic analysis of pulmonary blastoma\",\"authors\":\"Najmeh Alirezaie , Anne-Laure Chong , Felix K.F. Kommoss , Nelly Sabbaghian , Jose Camacho Valenzuela , Dylan Pelletier , Javad Nadaf , Shailesh B. Kolekar , Pradeesh Sivapalan , Mark G. Evans , Paul S. Thorner , Pierre-Olivier Fiset , Andreas von Deimling , William D. Foulkes\",\"doi\":\"10.1016/j.lungcan.2024.107916\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>Pulmonary blastoma is a rare, biphasic, adult-onset lung tumor. In this study, we investigate whether DICER1 pathogenic variants are a feature of pulmonary blastomas through in-depth analysis of the molecular events defining them.</p></div><div><h3>Methods</h3><p>We performed exome-wide sequencing and DNA methylation profiling of 8 pulmonary blastomas from 6 affected persons.</p></div><div><h3>Results</h3><p>We identified biallelic somatic <em>DICER1</em> pathogenic variants in 7 of 8 cases. The remaining case had a solitary missense pathogenic variant in the RNase IIIb domain of DICER1. Six of 8 cases carried a <em>CTNNB1</em> hotspot variant and 4 of 8 had a somatic pathogenic variant in <em>TP53</em>. Methylation analysis showed that the pulmonary blastomas clustered with other <em>DICER1</em>-mutated tumors and not with other more common types of lung cancer.</p></div><div><h3>Conclusion</h3><p>We conclude somatic <em>DICER1</em> pathogenic variants are the major driver of pulmonary blastoma and are likely to act in conjunction with <em>CTNNB1</em> hotspot variants that are often present.</p></div>\",\"PeriodicalId\":18129,\"journal\":{\"name\":\"Lung Cancer\",\"volume\":\"195 \",\"pages\":\"Article 107916\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0169500224004501\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224004501","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Exomic and epigenomic analysis of pulmonary blastoma
Objective
Pulmonary blastoma is a rare, biphasic, adult-onset lung tumor. In this study, we investigate whether DICER1 pathogenic variants are a feature of pulmonary blastomas through in-depth analysis of the molecular events defining them.
Methods
We performed exome-wide sequencing and DNA methylation profiling of 8 pulmonary blastomas from 6 affected persons.
Results
We identified biallelic somatic DICER1 pathogenic variants in 7 of 8 cases. The remaining case had a solitary missense pathogenic variant in the RNase IIIb domain of DICER1. Six of 8 cases carried a CTNNB1 hotspot variant and 4 of 8 had a somatic pathogenic variant in TP53. Methylation analysis showed that the pulmonary blastomas clustered with other DICER1-mutated tumors and not with other more common types of lung cancer.
Conclusion
We conclude somatic DICER1 pathogenic variants are the major driver of pulmonary blastoma and are likely to act in conjunction with CTNNB1 hotspot variants that are often present.
期刊介绍:
Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.